Amycretin: Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

Most weight-related peptides in the news act on a single pathway. Amycretin is unusual: it is one molecule engineered to switch on two of the body's appetite-signaling systems at the same time - the GLP-1 receptor that the semaglutide class targets, and the amylin receptor. Novo Nordisk has moved it toward later-stage testing, and it comes in both a tablet and an injection. So what did the early research actually find, and what is still unknown?

What researchers actually studied

In a 2025 Phase 1b/2a randomized study, researchers evaluated the once-weekly injectable form of amycretin in adults who were overweight or living with obesity, measuring change in body weight over the trial window against placebo. The trial reported an average body-weight reduction of roughly 22% in the highest injectable group over the study period - a figure reported in the trial, from a small early-phase cohort, not a confirmed real-world outcome. Separate early work has examined an oral version of the same molecule for comparable metabolic endpoints.

What people report

Because amycretin is not available for human use, there is no legitimate community of people using it outside of clinical trials - and that is an important distinction. Online interest is largely investors, biotech watchers, and people already using approved GLP-1 medicines wondering what comes next. Any first-hand 'review' of amycretin sold online is a red flag: a compound in early trials is not something a person can legitimately obtain, so such claims are anecdote at best and a safety and legality concern at worst.

What the evidence does not show

The early figures are eye-catching, but they answer a narrow question. The studies so far are small, short, and early-phase, so they do not tell us how amycretin performs over the long run, how durable any change is after stopping, how it compares head-to-head against established options in a large trial, or what its full safety picture looks like across a broad population. A promising Phase 1b/2a signal has historically been no assurance of a successful Phase 3 - many candidates that looked strong early did not survive larger testing.

Known and theoretical risks

In its class, the most commonly reported side effects are gastrointestinal - nausea, vomiting, and reduced appetite - and early amycretin trials reported a similar pattern, most often when the amount was increased quickly. Because the human dataset is small and short, the full safety profile is not yet characterized, and rarer or longer-term risks may not have surfaced. There is a separate, serious concern worth stating plainly: any product marketed online as 'amycretin' is not a legitimate approved medicine, cannot be quality-assured, and may be mislabeled, contaminated, or something else entirely - a real supply-safety and legal risk.

Regulatory status

Amycretin is investigational. It is not approved by the FDA, is not a prescription medicine, and is not available or legal for human use outside of a registered clinical trial. Its safety and efficacy in people have not been established. Any claim that it is approved, or any offer to sell it for personal use, is inaccurate and a warning sign.

References & sources

1. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (The Lancet, 2025).
2. Investigation of oral amycretin (NNC0487-0111) tablets in participants with obesity - ClinicalTrials.gov study record NCT06049329.